期刊
ANNALS OF ONCOLOGY
卷 27, 期 3, 页码 546-547出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdv580
关键词
-
类别
Nivolumab has shown promising early results in patients with advanced malignancies, including melanoma and lung cancer, with generally manageable side effects. On the other hand, recent studies showed that the immune activation caused by PD-1 blockade might promote severe autoimmune toxicity. Herein, we report a case of idiopathic thrombocytopenic purpura during nivolumab therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据